Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.

Bukkems, VeraNecsoi, CocaTenorio, Carmen HidalgoGarcia, CoralRockstroh, JürgenSchwarze-Zander, CarolineLambert, John SBurger, DavidKonopnicki, DeborahColbers, Angela2023-02-082023-02-082020http://hdl.handle.net/10668/15427This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective concentration (EC90). Clinical Trials Registration. NCT00825929.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/HIVcobicistatelvitegravirpharmacokineticspregnancyAnti-HIV AgentsAnti-Retroviral AgentsFemaleHIV InfectionsHumansPregnancyPregnancy Complications, InfectiousPregnancy Trimester, ThirdPregnant WomenQuinolonesClinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.research article32330231open access10.1093/cid/ciaa4881537-6591PMC7744974https://academic.oup.com/cid/article-pdf/71/10/e714/34933369/ciaa488.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744974/pdf